Sugi Predict

Sugi Predict / Compounds / SCHEMBL5751932

SCHEMBL5751932

SCHEMBL5751932

COC(=O)C1(C#N)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ EPHX2 P34913 1/20 0.41
▸ JAK2 O60674 2/20 0.40
▸ JAK1 P23458 2/20 0.40
▸ CTSK P43235 1/20 0.40
▸ EPHX1 P07099 1/20 0.40
▸ GPR119 Q8TDV5 2/20 0.39
▸ PKM P14618 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL388054 0.85 USP2 (0.46) USP2SMN1; SMN2EPHX2JAK2JAK1
SCHEMBL386890 0.85 SMN1; SMN2 (0.41) USP2SMN1; SMN2JAK2JAK1CTSK
SCHEMBL3105218 0.84 USP2 (0.45) USP2SMN1; SMN2EPHX2JAK2JAK1
SCHEMBL16123354 0.83 ALDH1A1 (0.41) USP2SMN1; SMN2EPHX2CTSKEPHX1
SCHEMBL15448332 0.83 USP2 (0.42) USP2SMN1; SMN2EPHX2EPHX1GPR119
SCHEMBL3105397 0.81 USP2 (0.43) USP2SMN1; SMN2EPHX2JAK2JAK1
SCHEMBL7014148 0.81 USP2 (0.45) USP2SMN1; SMN2EPHX2JAK2JAK1
SCHEMBL4287443 0.80 USP2 (0.50) USP2SMN1; SMN2EPHX2EPHX1GPR119
SCHEMBL6896870 0.80 CYP1A2 (0.37) USP2SMN1; SMN2EPHX2MEN1ALDH1A1
SCHEMBL17632152 0.79 USP2 (0.41) USP2SMN1; SMN2JAK2JAK1CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441704-B2 Compounds active towards nuclear receptors NUEVOLUTION A/S (DK) 2025-10-14 — — US disclosed
US-20230382924-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382924-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382924-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230271937-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NUEVOLUTION A/S (DK) 2023-08-31 — — US disclosed
US-20230271937-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NUEVOLUTION A/S (DK) 2023-08-31 — — US disclosed
EP-4225446-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
US-11685727-B2 Compounds active towards nuclear receptors NUEVOLUTION A/S (DK) 2023-06-27 — — US disclosed
EP-4076661-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS Nuevolution A/S (DK) 2022-10-26 — — EP disclosed
WO-2022076621-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
WO-2021124279-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NUEVOLUTION A/S (DK) 2021-06-24 — — WO disclosed
WO-2021124279-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NUEVOLUTION A/S (DK) 2021-06-24 — — WO disclosed
WO-2015150337-A1 LIM KINASE INHIBITORS AMAKEM NV (BE) 2015-10-08 — — WO disclosed
WO-2015150337-A1 LIM KINASE INHIBITORS AMAKEM NV (BE) 2015-10-08 — — WO disclosed
EP-1419155-B1 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2006-11-08 — — EP disclosed
US-20040198756-A1 Medicaments SMITHKLINE BEECHAM PLC (GB) 2004-10-07 — — US disclosed
EP-1419155-A2 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2004-05-19 — — EP disclosed
US-20040072802-A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha DUAN JINGWU (US) 2004-04-15 — — US disclosed
US-20040072802-A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha DUAN JINGWU (US) 2004-04-15 — — US disclosed
WO-2003010138-A2 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2003-02-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685727-B2 Compounds active towards nuclear receptors NCOA1, NR1H2, NCOA3 USP2 4401/4885SMN1; SMN2 4320/4885EPHX2 3679/4885
US-20040072802-A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha TNF, XPNPEP1, MMP2 USP2 740/4885SMN1; SMN2 3515/4885EPHX2 1266/4885
US-20040198756-A1 Medicaments PIGO, PSAP, CD68 USP2 2709/4885SMN1; SMN2 3564/4885EPHX2 4556/4885
US-20230271937-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NCOA1, NR1H2, NCOA3 USP2 4401/4885SMN1; SMN2 4320/4885EPHX2 3679/4885
US-12441704-B2 Compounds active towards nuclear receptors NCOA1, NR1H2, NCOA3 USP2 4401/4885SMN1; SMN2 4320/4885EPHX2 3679/4885
US-20230382924-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B USP2 2128/4885SMN1; SMN2 4840/4885EPHX2 3150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.